During the past 3 years, the average EBITDA Per Share Growth Rate was -50.70% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Elicio Therapeutics was -50.70% per year. The lowest was -266.70% per year. And the median was -158.70% per year.
Competitive Comparison of Elicio Therapeutics's 3-Year EBITDA Growth Rate
For the Biotechnology subindustry, Elicio Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elicio Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elicio Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Elicio Therapeutics's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Elicio Therapeutics 3-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Elicio Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Elicio Therapeutics (Elicio Therapeutics) Business Description
Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking. Elicio is engineering lymph node-targeted AMPlifiers, immunomodulators, adjuvants, and vaccines for an array of aggressive cancers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELTX has been successfully added to your